Healthy women possessing a certain abnormality on MRIs are nine times more likely to get breast cancer, according to research published in Radiology. The abnormality is called background parenchymal enhancement (BPE), a phenomenon in which areas of normal background breast tissue appear white, or enhanced.
The magnitude of the link was so strong, it could lead to improved cancer detection and therapy, if future research concurs.
“The degree of the impact of BPE on risk for developing breast cancer was surprising,” senior author, and Seattle Cancer Care Alliance Director of Radiology, Constance Lehman, M.D., Ph.D., FACR, told Bioscience Technology. “While we hypothesized BPE would increase a woman’s risk of developing breast cancer, we did not predict over a 9 fold increased risk.”
The impact may go far beyond finding cancer earlier.
http://www.biosciencetechnology.com/articles/2015/05/women-mri-abnormality-nine-times-more-likely-get-breast-cancer
Sunday, May 24, 2015
Vanessa Kachadurian Bioscience - New COPD drug clears Phase III
Novartis ($NVS), working to get a pair of Europe-approved COPD treatments onto the U.S. market, reported some positive Phase III data while awaiting final word from the FDA.
The two inhaled treatments are NVA237, a bronchodilator marketed as Seebri Breezhaler overseas, and QVA149, which combines the active ingredient in NVA237 with Novartis' approved Onbrez.
In one Phase III program, the twice-daily QVA149 met its goals of significantly improving COPD patients' lung function compared to placebo and its individual components alone. The inhaler also met its secondary goals of improving breathlessness and quality of life, Novartis said. And in two separate late-stage studies, NVA237 beat placebo in improving lung function, meeting its primary endpoint. Both treatments charted a similar profile to placebo and their comparator agents, the company said.
http://www.fiercebiotech.com/story/novartis-duo-copd-drugs-clears-phase-iii-path-fda-decision/2015-05-22
In one Phase III program, the twice-daily QVA149 met its goals of significantly improving COPD patients' lung function compared to placebo and its individual components alone. The inhaler also met its secondary goals of improving breathlessness and quality of life, Novartis said. And in two separate late-stage studies, NVA237 beat placebo in improving lung function, meeting its primary endpoint. Both treatments charted a similar profile to placebo and their comparator agents, the company said.
http://www.fiercebiotech.com/story/novartis-duo-copd-drugs-clears-phase-iii-path-fda-decision/2015-05-22
Subscribe to:
Posts (Atom)